Saturday 17 October 2026
Export NVCT’s income statement to Excel — free account
Nuvectis Pharma, Inc.
NVCT Healthcare Biotechnology
In the quarter to June 2026, EPS was flat and free cash flow fell 34.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
18.48
0.45
−2.38%
Follow NVCT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
3.07 | 2.38 | 2.27 | 1.68 |
Net Debt/EBITDA |
4.55 | 4.15 | 4.01 | 3.08 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.45 | 0.54 | 1.08 | 0.65 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.20) | (0.18) | (0.28) | (0.19) | |
Cash per Share |
1.56 | 1.45 | 1.07 | 0.94 | |
Shareholders Equity per Share |
1.06 | 0.84 | 0.61 | 0.39 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.06 | 0.84 | 0.61 | 0.39 | |
Free Cash Flow |
(4.49) | (3.97) | (6.51) | (4.53) | |
Working Capital |
24.01 | 18.41 | 14.22 | 9.08 | |
Net Current Asset Value |
24.01 | 18.41 | 14.22 | 9.08 | |
| Other line items | |||||
Quick Ratio |
3.06 | 2.38 | 2.25 | 1.67 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.20) | (0.18) | (0.28) | (0.19) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
4.35 | 4.39 | 3.84 | 5.08 | |
Average Assets |
26.45 | 25.16 | 27.77 | 24.69 | |
Average Common Equity |
17.50 | 14.06 | 17.59 | 12.98 |
Columns are period end dates